Fig. 6: ANTXR1-positive cardiac fibroblasts promote heart damage in vivo.
From: ANTXR1 blockade enhances cardiac function in preclinical models of heart failure
a, Co-IF staining for ANTXR1 (green) and PDGFRA (red) in the LV 14 days following MI or 28 days of treatment with ATII/PE. Scale bar, 100 µm. b, Co-IF staining for ANTXR1 (green) and COL1 (red) in the LV 14 days following MI. Image is representative of at least three biological specimens. Scale bar, 100 µm. c, Cardiac EF% and FS% 5 weeks post-MI in fibroblast conditional Antxr1 KO mice. n = 18 (Antxr1+/+ and Antxr1+/fl) or 19 (Antxr1fl/fl) mice per group at baseline. d, Cardiac EF%, FS%, GLS and ratio of early diastolic mitral inflow velocity to early diastolic mitral annulus velocity (MV E/e’) following 28 days of ATII/PE treatment in fibroblast conditional KO mice. Baseline: n = 6 (Antxr1+/+) or 4 (Antxr1+/fl); ATII/PE: n = 13 (Antxr1+/+) or 6 (Antxr1+/fl)/mice group. e, Co-IF staining for CHP (red) and WGA (green) in LV after 28 days of ATII/PE. Scale bar, 100 µm. f, Quantification of CHP staining. n = 4 (Antxr1+/+) or 3 (Antxr1+/fl) hearts per group. Results represent mean ± s.e.m. P values were derived from a one-way ANOVA with Tukey’s post hoc test (c,d) or an unpaired, two-tailed t-test (f). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
